Loading...

DiaSorin S.p.A.

DSRLFPNK
Healthcare
Medical - Diagnostics & Research
$107.68
$0.00(0.00%)

DiaSorin S.p.A. DSRLF Peers

See (DSRLF) competitors and their performances in Stock Market.

Peer Comparison Table: Medical - Diagnostics & Research Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
DSRLF$107.68+0.00%5.9B26.96$4.03+1.10%
LZAGY$70.56-1.12%51.3B64.00$1.11+0.59%
LZAGF$716.80+0.20%49.6B65.50$11.09+0.34%
WUXAY$10.25+0.00%28.5B18.80$0.54+3.22%
WUXIF$7.34+0.00%20.1B13.59$0.54+0.25%
BMXMF$142.45+0.00%15.8B31.81$4.22+0.73%
ERFSF$73.25+2.10%12.9B30.43$2.40+0.97%
SKHCF$18.26+1.39%8.8B25.01$0.73+3.84%
SKHHY$18.05+1.29%8.5B23.89$0.74+3.82%
HNGZY$4.00+0.00%5.3B26.67$0.15+1.03%
Showing 1 to 10 of 79 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

DSRLF vs LZAGY Comparison

DSRLF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DSRLF stands at 5.9B. In comparison, LZAGY has a market cap of 51.3B. Regarding current trading prices, DSRLF is priced at $107.68, while LZAGY trades at $70.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DSRLF currently has a P/E ratio of 26.96, whereas LZAGY's P/E ratio is 64.00. In terms of profitability, DSRLF's ROE is +0.09%, compared to LZAGY's ROE of +0.06%. Regarding short-term risk, DSRLF is less volatile compared to LZAGY. This indicates potentially lower risk in terms of short-term price fluctuations for DSRLF.

Stock Price Comparison

Loading...

Frequently Asked Questions

;